IBRX - ImmunityBio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
IBRX price evolution
IBRX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $4.9 | $2.06 | $2.14 | $3.17 |
| Inventory | $1.96 | $1.81 | ||
| Total current assets | $163.15 | $242.83 | $195.72 | $294.08 |
| Long term investments | ||||
| Property, plant & equipment | $174.23 | $175.79 | $178.75 | $182.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $364.57 | $444.32 | $400.68 | $504.45 |
| Current liabilities | ||||
| Accounts payable | $9.95 | $20.32 | $13.87 | $9.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $60.96 | $62.11 | $53.76 | $58.28 |
| Long term debt | $972.77 | $956.26 | $850.5 | $836.95 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1109.72 | $1142.71 | $1092.69 | $1091.44 |
| Shareholders' equity | ||||
| Retained earnings | -$3316.09 | -$3230.36 | -$3095.79 | -$2961.68 |
| Other shareholder equity | $0.1 | -$0.01 | -$0.01 | $0.01 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11.44 | |||
| Short term investments | ||||
| Net receivables | $3.17 | $1.89 | $1.33 | $5 |
| Inventory | ||||
| Total current assets | $294.08 | $140.58 | $334.35 | $75.5 |
| Long term investments | ||||
| Property, plant & equipment | $182.68 | $189.58 | $119.17 | $53.93 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $76.36 | |||
| Total investments | ||||
| Total assets | $504.45 | $362.36 | $468.91 | $151.86 |
| Current liabilities | ||||
| Accounts payable | $9.2 | $21.02 | $11.42 | $9.37 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $58.28 | $500.86 | $369 | $24.65 |
| Long term debt | $836.95 | $241.34 | $306.35 | $254.4 |
| Total noncurrent liabilities | $9.81 | |||
| Total debt | ||||
| Total liabilities | $1091.44 | $809.68 | $711.08 | $34.47 |
| Shareholders' equity | ||||
| Retained earnings | -$2961.68 | -$2378.49 | -$1961.92 | -$754.57 |
| Other shareholder equity | $0.01 | $0.18 | $0 | -$0.12 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.11 | $1.05 | $0.04 | $0.14 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $86.36 | $100.38 | $95.24 | $84.64 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.04 | |||
| Interest expense | -$38.51 | -$17.73 | -$37.11 | -$70.44 |
| Net income | ||||
| Net income | -$85.73 | -$134.56 | -$134.11 | -$233.39 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.62 | $0.24 | $0.11 | |
| Cost of revenue | ||||
| Gross Profit | $0.11 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $361.99 | $350.86 | $91.74 | |
| Operating income | -$91.63 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.04 | $0.03 | $0.01 | |
| Interest expense | -$173.66 | -$63.77 | $0.04 | |
| Net income | ||||
| Net income | -$583.2 | -$416.57 | -$92.38 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$22.08 | -$87.11 | -$35.62 | -$30.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $174.7 | $159.12 | $10.22 | $558.34 |
| Effect of exchange rate | -$0.02 | -$0.03 | -$0.04 | -$0.29 |
| Change in cash and equivalents | -$153.49 | -$135.35 | -$132.42 | $160.82 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$92.38 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$70.45 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$30.47 | $27.3 | -$84.89 | -$20.59 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $558.34 | $233.61 | $505.44 | $86.97 |
| Effect of exchange rate | -$0.29 | $0.28 | $0.05 | |
| Change in cash and equivalents | $160.82 | -$76.32 | $146.18 | -$4.07 |
News
Fundamentals
| Market cap | $2.24B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 696.83M |
| Revenue | $7.33M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$587.79M |
| Revenue Q/Q | 5.07K% |
| Revenue Y/Y | N/A |
| P/E ratio | -3.82 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 306.03 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.84 |
|---|---|
| ROA | -137.17% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.68 |
| Quick ratio | 2.64 |